secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2025-08-27T23:59:59+00:00
Accession:  0001193125-25-189765
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena PRX012 shows amyloid reduction but higher ARIA-E rates; seeks partnership
--------------------------------------------------------------------------------

- Phase 1 ASCENT: PRX012 400 mg achieved mean amyloid PET reduction to 27.47 CL at month 12.
- ARIA-E rates at 400 mg (41.7%) and 200 mg (38.1%) exceeded those of FDA-approved anti-Aβ antibodies.
- One death in 45 mg cohort deemed unrelated to study drug; injection site reactions low (4.1%).
- Company plans to explore partnership to advance PRX012 and preclinical PRX012-TfR antibody.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000119312525189765/0001193125-25-189765-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000119312525189765/d38911d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-189765

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer